Progress in Medical Physics (한국의학물리학회지:의학물리)

Korean Society of Medical Physics (한국의학물리학회)
권호 표지
DOI QR코드

DOI QR Code

Feasibility Assessment of Physical Factors of Rectal Cancer Short-Course Chemoradiotherapy with Delayed Surgery

  • Koo, Jihye (Department of Physics, University of South Florida) ;
  • Chung, Mijoo (Department of Radiation Oncology, Kyung Hee University Hospital at Gangdong) ;
  • Chung, Weon Kuu (Department of Radiation Oncology, Kyung Hee University Hospital at Gangdong) ;
  • Jin, Sunsik (Department of Radiation Oncology, Kyung Hee University Hospital at Gangdong) ;
  • Kim, Dong Wook (Department of Radiation Oncology, Kyung Hee University Hospital at Gangdong)
  • Received : 2018.11.21
  • Accepted : 2018.12.18
  • Published : 2018.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

To verify the correlations between the clinical outcomes and physical factors of short-course chemoradiotherapy (SCRT) and long-course chemoradiotherapy (LCRT) with delayed surgery in patients with rectal cancer. Seventy-two patients with rectal cancer were enrolled in this study. Nineteen patients were treated with SCRT (25 Gy, 5 fractions) by intensity-modulated radiation therapy (IMRT), and 53 patients were treated with LCRT (50.4 Gy, 28 fractions) by three-dimensional conformal radiation therapy (3DCRT). Various physical factors for the target and organs at risk (OARs) were calculated to compare the clinical outcomes. The organ equivalent dose (OED) and lifetime attributable risk (LAR) of bowels and bladders were similar between the SCRT and LCRT groups, whereas the values of femurs were higher in the LCRT group. The equivalent uniform dose and normal tissue complication probability were higher in the LCRT than the SCRT group for most organs. Treatment complications, including anastomotic leakage, bowel adhesion, and hematologic toxicity, were not significantly different between SCRT and LCRT groups. CIs were $0.84{\pm}0.2$ and $0.61{\pm}0.1$ for SCRT and LCRT, respectively. The CVIs were $1.07{\pm}0.0$ and $1.10{\pm}0.1$, and the HIs were $0.09{\pm}0.0$ and $0.11{\pm}0.1$ for SCRT and LCRT, respectively. The sphincter-saving rates were 89.5% and 94.3% for SCRT and LCRT, respectively. The complete pathologic remission rates were 21.1% and 13.2%, and the down-staging rates were 47.4% and 26.4% for SCRT and LCRT, respectively. SCRT with IMRT is comparable to conventional LCRT in both physical indexes and clinical outcome. The preoperative SCRT, compensated by IMRT, is an effective and safe modality.

Keywords

References

  1. Graf W, Dahlberg M, Osman MM, Holmberg L, Pahlman L, Glimelius B. Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiother Oncol. 1997;43:133-7. https://doi.org/10.1016/S0167-8140(96)01867-1
  2. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30:3827-33. https://doi.org/10.1200/JCO.2012.42.9597
  3. Van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985-90. https://doi.org/10.1016/S0140-6736(05)67070-5
  4. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-40. https://doi.org/10.1056/NEJMoa040694
  5. Chung M, Kim D, Chung W, Lee S, Jeong S, Hwang J, et al. Preoperative short-vs. long-course chemoradiotherapy with delayed surgery for locally advanced rectal cancer. Oncotarget. 2016.
  6. Glimelius B. Rectal cancer irradiation. Long course, short course or something else? Acta Oncol. 2006;45:1013-7. https://doi.org/10.1080/02841860601019413
  7. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-23. https://doi.org/10.1056/NEJMoa060829
  8. Radu C, Berglund A, Pahlman L, Glimelius B. Shortcourse preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol. 2008;87:343-9. https://doi.org/10.1016/j.radonc.2007.11.025
  9. Mu X, Lofroth PO, Karlsson M, Zackrisson B. The effect of fraction time in intensity modulated radiotherapy: theoretical and experimental evaluation of an optimisation problem. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2003;68:181-7. https://doi.org/10.1016/S0167-8140(03)00165-8
  10. Fenkell L, Kaminsky I, Breen S, Huang S, Van Prooijen M, Ringash J. Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2008;89:287-91. https://doi.org/10.1016/j.radonc.2008.08.008
  11. Arbea L, Ramos LI, Martinez-Monge R, Moreno M, Aristu J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiation oncology. 2010;5:17. https://doi.org/10.1186/1748-717X-5-17
  12. Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. International journal of radiation oncology, biology, physics. 2004;59:267-84. https://doi.org/10.1016/j.ijrobp.2004.01.024
  13. Fenoglietto P, Laliberte B, Allaw A, Ailleres N, Idri K, Hay MH, et al. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2008;88:77-87. https://doi.org/10.1016/j.radonc.2007.12.011
  14. W.H.O. Life Expectancy at Birth (years). 2015.
  15. E.P.A. EPA Radiogenic Cancer Risk Models and Projections for the U.S. Population. 2008.
  16. Brodin NP, Munck Af Rosenschold P, Aznar MC, Kiil-Berthelsen A, Vogelius IR, Nilsson P, et al. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncol. 2011;50:806-16. https://doi.org/10.3109/0284186X.2011.582514
  17. Kim DW, Chung WK, Yoon M. Imaging doses and secondary cancer risk from kilovoltage cone-beam CT in radiation therapy. Health physics. 2013;104:499-503. https://doi.org/10.1097/HP.0b013e318285c685
  18. Surveillance, Epidemiology, and End Results (SEER).
  19. National Research Council of the National Academies. Health risks from exposure to low levels of ionizing radiation, BEIR VII Phase 2. 2006 (Washington DC: The national Academic Press).
  20. Sun Young Moon MY, Weon Kuu Chung, Mijoo Chung, Dong Oh Shin, Dong Wook Kim. Comparison of Dosimetric Parameters of Patient with Large and Pendulous Breast Receiving Breast Radiotherapy in the Prone versus Supine Position. Prog Med Phys. 2015;26:7.
  21. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. International journal of radiation oncology, biology, physics. 1991;21:109-22.